You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.
The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.